论文部分内容阅读
本院自1986年7月至1987年12月随机分组采用UD(UFT、DDP)和UM(UFT、MMC)两方案治疗晚期胃癌29例,男性20例,女性9例,全组均经病理确诊。UD方案为UFT200mg每日三次,口服14天;DDP100mg加入盐水500ml静滴,第1天,加水化利尿。UM方案为UFT200mg每日三次,口服14天;MMC10mg静注,第1天,上述方案每月重复用药。结果表明,UM组11例中6例获得PR(54%)。有效者中位生存期120天,无效者90天。UD组18例中10例获得PR(55％)。有效者中位生存期145天,无效者90天。常见毒副反应为恶心呕吐及乏力。UD组比UM组为多。无明显肝肾功能损害。骨髓抑制轻。初步观察UD与UM方案对晚期胃癌均有一定的近期疗效。但二组无显著差异,值得进一步研究。
In the hospital from July 1986 to December 1987, 29 cases of advanced gastric cancer were treated with UD (UFT, DDP) and UM (UFT, MMC) regimens. There were 20 males and 9 females. The whole group was diagnosed by pathology. . The UD program was UFT200mg three times daily, orally for 14 days; DDP 100mg added saline 500ml intravenous infusion, on the first day, hydration diuresis. The UM regimen was UFT200mg three times daily, orally 14 days; MMC 10mg intravenously, on the first day, the above regimen was repeated every month. The results showed that 6 out of 11 cases in the UM group received PR (54%). The effective median survival time is 120 days, and the invalid is 90 days. 10 out of 18 patients in the UD group received PR (55%). The effective median survival time was 145 days, and the effective ones were 90 days. Common toxicities are nausea, vomiting and fatigue. There are more UD groups than UM groups. No significant liver and kidney damage. Myelosuppression is light. The initial observation of the UD and UM regimens has a certain short-term efficacy in advanced gastric cancer. However, there was no significant difference between the two groups and it is worth further study.